HAART for HIV-1 infection: Zeroing in on when to start

Archives of Internal Medicine

Volumn 171, Issue 17, 2011, Pages 1569-1570

  Kuritzkes, Daniel R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; COMORBIDITY; DRUG INDICATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NEUROLOGIC DISEASE; NOTE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEROCONVERSION; STATISTICAL SIGNIFICANCE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE;

EID: 80053367755     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2011.402     Document Type: Note

References (10)

1. Clumeck N, Pozniak A, Raffi F; EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med. 2008;9(2):65-71. (Pubitemid 351228129)
2. Thompson MA, Aberg JA, Cahn P, et al International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304(3):321-333.
3. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC: Dept of Health and Human Services; January 1, 2011:1-166. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL .pdf. Accessed June 26, 2011.
4. Gazzard BG, Anderson J, Babiker A, et al BHIVA Treatment Guidelines Writing Group. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 2008;9(8):563-608.
5. Kitahata MM, Gange SJ, Abraham AG, et al NA-ACCORD Investigators. Effect of early versus deferred antiretroviral therapy forHIVon survival.NEngl J Med. 2009;360(18):1815-1826.
6. Kuller LH, Tracy R, Belloso W, et al INSIGHT SMART Study Group. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5(10):e203.
7. Sterne JA, May M, Costagliola D, et al When To Start Consortium. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373(9672): 1352-1363.
8. Writing Committee for the CASCADE Collaboration. Timing of HAART initation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. Arch Intern Med. 2011;171(17):1560-1569.
9. Cain LE, Logan R, Robins JM, et al HIV-CAUSAL Collaboration. When to initiate combined antiretroviral therapy to reduce mortality and AIDSdefining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med. 2011;154(8):509-515.
10. Bhaskaran K, Hamouda O, Sannes M, et al CASCADE Collaboration. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA. 2008;300(1):51-59. (Pubitemid 351920404)